RFC40 Modulation for Triple-Negative Breast Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current breast cancer treatments lack effective therapies for triple-negative breast cancer (TNBC) and other receptor-negative forms, as they primarily target estrogen and growth factor receptors, leading to resistance and recurrence issues.
Innovation Solution
RFC40 is identified as a non-receptor based molecular marker and target for breast cancer diagnosis and therapy, with methods involving modulation or inhibition of its expression or activity using siRNAs, miRNAs, and other inhibitors to reduce cell proliferation and division.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional endocrine and growth factor receptor-based therapies are used for breast cancer treatment, then treatment effectiveness is improved for estrogen-positive and HER2-positive cancers, but treatment fails for triple-negative breast cancer (TNBC) and receptor-negative forms
Solution Approach 1:
The patent identifies RFC40 as a universal therapeutic target that functions across all breast cancer subtypes regardless of receptor status. RFC40 is involved in DNA replication and cell proliferation processes that are fundamental to all rapidly dividing cancer cells, making it a multi-functional target applicable to estrogen-positive, estrogen-negative, progesterone-negative, and HER2-negative cancers where traditional receptor-based therapies fail.
Solution Approach 2:
The patent shifts the therapeutic parameter from receptor-specific targeting to a fundamental cellular process target. By targeting RFC40, which is essential for DNA replication and cell cycle progression, the therapy changes from ligand-receptor interaction parameters to cellular proliferation parameters, enabling effectiveness across all breast cancer subtypes.
2Reliability
If long-term endocrine therapy is used for breast cancer, then initial treatment response is achieved, but resistance develops over time leading to recurrence
Solution Approach 1:
The patent extracts the therapeutic strategy from the failing endocrine pathway and relocates it to a different molecular target (RFC40) that is not subject to the same resistance mechanisms. By taking out the therapy from the estrogen receptor pathway where resistance has developed and applying it to RFC40, which regulates fundamental DNA replication processes, the treatment bypasses acquired resistance while maintaining effectiveness.
Solution Approach 2:
Instead of continuing to target the same receptor pathway that has led to resistance, the patent inverts the approach by targeting a completely different molecular mechanism (RFC40-mediated DNA replication) that is equally critical for cancer cell survival but operates through a different biological pathway, thereby reversing the resistance problem.
3Productivity
If more aggressive chemotherapy is used to treat TNBC, then tumor growth is temporarily suppressed, but toxicity increases and therapeutic window narrows
Solution Approach 1:
The patent introduces RFC40 inhibition as an intermediary mechanism that bridges the gap between effective cancer cell killing and reduced toxicity. By targeting RFC40, which is specifically critical for rapidly dividing cancer cells but less critical for normal quiescent cells, the therapy achieves tumor growth suppression through a more selective mechanism that spares normal tissues, thereby reducing therapeutic toxicity while maintaining productivity.
Data Source
AI summary
The present disclosure relates generally to cancer and particularly to breast cancer including estrogen sensitive, estrogen resistant and triple negative breast cancer (TNBC), and to methods of diagnosis and prognosis thereof and therapeutic intervention involving replication factor C 40 (RFC40). Methods and assays for evaluating breast cancer are provided. The disclosure also relates to inhibition or modulation of RFC40 in treatment or alleviation of cancer, including breast cancer. RFC40 inhibitors, including siRNAs and miRNAs, which specifically affect cancer cells, particularly breast cancer cells, are provided.